NYSE:ABT • US0028241000
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for ABBOTT LABORATORIES (ABT).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-03-11 | Citigroup | Maintains | Buy -> Buy |
| 2026-02-02 | Barclays | Maintains | Overweight -> Overweight |
| 2026-01-23 | Bernstein | Maintains | Outperform -> Outperform |
| 2026-01-23 | BTIG | Maintains | Buy -> Buy |
| 2026-01-23 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2026-01-23 | RBC Capital | Maintains | Outperform -> Outperform |
| 2026-01-23 | Evercore ISI Group | Maintains | Outperform -> Outperform |
| 2026-01-23 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2026-01-23 | Citigroup | Maintains | Buy -> Buy |
| 2026-01-09 | Bernstein | Maintains | Outperform -> Outperform |
| 2026-01-05 | Barclays | Maintains | Overweight -> Overweight |
| 2025-11-20 | BTIG | Reiterate | Buy -> Buy |
| 2025-10-17 | Barclays | Maintains | Overweight -> Overweight |
| 2025-10-16 | RBC Capital | Reiterate | Outperform -> Outperform |
| 2025-10-16 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2025-10-16 | Evercore ISI Group | Maintains | Outperform -> Outperform |
| 2025-10-16 | Raymond James | Maintains | Outperform -> Outperform |
| 2025-10-15 | BTIG | Reiterate | Buy -> Buy |
| 2025-10-10 | Benchmark | Initiate | Buy |
| 2025-10-07 | Evercore ISI Group | Maintains | Outperform -> Outperform |
| 2025-07-18 | Mizuho | Maintains | Neutral -> Neutral |
| 2025-07-18 | BTIG | Maintains | Buy -> Buy |
| 2025-07-18 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2025-07-18 | Raymond James | Maintains | Outperform -> Outperform |
| 2025-07-18 | Jefferies | Upgrade | Hold -> Buy |
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 40.109B -8.12% | 41.95B 4.59% | 44.328B 5.67% | 48.272B 8.90% | 51.841B 7.39% | 55.48B 7.02% | 59.182B 6.67% | 63.47B 7.25% | 67.627B 6.55% | 72.345B 6.98% | 77.491B 7.11% | |
| EBITDA YoY % growth | 9.965B -16.78% | 10.211B 2.47% | 11.443B 12.07% | 13.109B 14.56% | 14.317B 9.22% | 15.518B 8.39% | 16.232B 4.60% | 19.36B 19.27% | N/A | N/A | N/A | |
| EBIT YoY % growth | 6.722B -22.80% | 6.993B 4.03% | 8.327B 19.08% | 11.467B 37.71% | 12.503B 9.03% | 13.63B 9.01% | 15.554B 14.12% | 17.187B 10.50% | N/A | N/A | N/A | |
| Operating Margin | 16.76% | 16.67% | 18.78% | 23.75% | 24.12% | 24.57% | 26.28% | 27.08% | N/A | N/A | N/A | |
| EPS YoY % growth | 4.44 -16.85% | 4.67 5.18% | 5.15 10.28% | 5.74 11.53% | 6.32 9.99% | 6.92 9.49% | 7.43 7.34% | 8.44 13.67% | 9.19 8.89% | 10.08 9.67% | 11.06 9.72% |
All data in USD
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | 1.16 6.44% | 1.40 11.01% | 1.47 12.99% | 1.65 9.69% | 1.38 18.83% | 1.56 11.38% | 1.63 11.22% | 1.77 7.42% |
| Revenue Q2Q % growth | 11.101B 7.17% | 12.017B 7.85% | 12.383B 8.92% | 12.915B 12.71% | 12.101B 9.01% | 12.992B 8.11% | 13.318B 7.55% | 13.876B 7.44% |
| EBITDA Q2Q % growth | 2.68B 7.93% | 3.192B -12.67% | 3.406B -24.34% | 3.776B -30.64% | 3.438B 28.28% | 3.682B 15.35% | 3.765B 10.54% | 3.934B 4.18% |
| EBIT Q2Q % growth | 2.278B 31.91% | 2.781B 31.06% | 2.955B 35.67% | 3.351B 43.94% | 2.888B 26.78% | 3.191B 14.74% | 3.318B 12.28% | 3.579B 6.80% |
All data in USD
35 analysts have analysed ABT and the average price target is 136.02 USD. This implies a price increase of 29.43% is expected in the next year compared to the current price of 105.095.
ABBOTT LABORATORIES (ABT) will report earnings on 2026-04-14, before the market open.
The consensus EPS estimate for the next earnings of ABBOTT LABORATORIES (ABT) is 1.16 USD and the consensus revenue estimate is 11.10B USD.
The number of analysts covering ABBOTT LABORATORIES (ABT) is 35.